Graham Capital Management’s Fate Therapeutics FATE Stock Holding History

Graham Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.2K	Sell	14,149 -50,617	-78%	-$93.7K	﹤0.01%	1209
2026 Q1	$77.7K	Sell	64,766 -130,813	-67%	-$159K	﹤0.01%	1067
2025 Q4	$192K	Sell	195,579 -273,492	-58%	-$328K	﹤0.01%	1056
2025 Q3	$591K	Buy	469,071 +383,438	+448%	+$413K	0.01%	559
2025 Q2	$95.9K	Sell	85,633 -54,431	-39%	-$63.3K	﹤0.01%	1205
2025 Q1	$111K	Buy	140,064 +117,722	+527%	+$144K	﹤0.01%	1202
2024 Q4	$36.9K	Buy	+22,342	New	+$56.3K	﹤0.01%	1187
2024 Q3	–	Sell	-11,565	Closed	-$37.9K	–	1169
2024 Q2	$37.9K	Buy	+11,565	New	+$50.6K	﹤0.01%	991
2023 Q4	–	Sell	-21,690	Closed	-$46K	–	1092
2023 Q3	$46K	Sell	21,690 -120,711	-85%	-$400K	﹤0.01%	966
2023 Q2	$678K	Buy	+142,401	New	+$786K	0.02%	471

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Graham Capital Management's FATE Position: Q2 2026 in Review

Graham Capital Management reduced its Fate Therapeutics (FATE) stake by 78% in Q2 2026, selling an estimated $93.7K and leaving 14,149 shares worth $38.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1209.

Graham Capital Management first reported a position in FATE in Q2 2023 and has held it in 10 quarters since. The position peaked at $678K in Q2 2023. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Graham Capital Management held 14,149 shares of Fate Therapeutics worth $38.2K as of Q2 2026.
Graham Capital Management sold 50,617 Fate Therapeutics shares in Q2 2026, an estimated $93.7K.
Fate Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1209 holding.
Graham Capital Management first reported a position in Fate Therapeutics in Q2 2023 and has held it in 10 quarters since.
Graham Capital Management's Fate Therapeutics position peaked at $678K in Q2 2023.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.